Leuzan

Quick links to important sections

Leuzan

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Leuzan

Quick Facts

Property Description
Active ingredient Tenofovir Disoproxil Fumarate (TDF)
Form Oral tablet
Pharmacological class Antiretroviral, Nucleotide Reverse Transcriptase Inhibitor (NtRTI)
Origin Synthetic Acyclic Nucleotide Prodrug

Leuzan: Definition and Active Composition

Leuzan is a prescription-only medicine containing the active ingredient Tenofovir Disoproxil Fumarate (TDF), which is formulated as an oral tablet. It is produced by Richmond Laboratories, a specific, commercially available version of the TDF compound. As a prodrug, TDF must be converted inside the body into the fully active agent, Tenofovir diphosphate (TFV-DP), a strategy clinically recognized for optimizing systemic delivery. This single-agent product forms a core component of the necessary combination therapy regimens used globally for chronic viral management.


What Type of Medicine is Leuzan?

Leuzan is classified as an antiretroviral drug, specifically belonging to the Nucleotide Reverse Transcriptase Inhibitor (NtRTI) pharmacological class. This classification indicates the medicine's primary role is to interfere with the reproduction cycle of certain viruses. Tenofovir is a synthetic acyclic nucleotide analog, structurally designed to compete with the natural building blocks of DNA. Pharmacological studies confirm this class's mechanism of action is highly effective at directly inhibiting key viral enzymes, offering a high barrier to resistance.


General Purpose of the Antiviral Action

The overall general purpose of Leuzan is to achieve sustained inhibition of viral replication, helping to control the amount of virus circulating in the patient's system. The drug works by inducing chain termination: when the active metabolite is incorporated into the viral DNA, it stops the copying process, preventing the virus from completing its reproduction cycle. By stopping the virus from multiplying at this genetic level, this medicine limits the infection's spread, which is vital for the long-term management of chronic viral diseases.

Regulatory References

  1. Tenofovir Disoproxil Fumarate EPAR (Viread)
  2. Tenofovir Disoproxil Fumarate Patient Drug Record

What side effects are possible with Leuzan?

Possible Side Effects and Safety Information: Leuzan

Leuzan belongs to the class of antibiotics known as fluoroquinolones. Regulatory authorities (such as the FDA and EMA) have mandated strong warnings regarding the risk of serious, disabling, and potentially permanent adverse reactions that can affect multiple body systems, including the musculoskeletal, nervous, and cardiovascular systems.

Serious and Disabling Adverse Reactions

The most significant safety concerns are highlighted in official labeling, often through a Boxed Warning in the United States. These serious effects include:

  • Tendinitis and Tendon Rupture: Inflammation or tearing of tendons, most commonly the Achilles tendon. This risk is higher in the elderly, those with kidney impairment, and patients taking corticosteroids. Onset can occur within hours of starting treatment or several months after stopping.
  • Peripheral Neuropathy: Damage to nerves outside the brain and spinal cord, potentially resulting in permanent numbness, tingling, burning pain, or weakness, particularly in the arms and legs.
  • Central Nervous System (CNS) Effects: These can include psychiatric reactions such as anxiety, depression, confusion, hallucinations, and suicidal thoughts or actions.
  • Cardiovascular Risks: An increased risk of developing an aortic dissection or rupture (a tear in the wall of the main artery) has been reported, especially in older patients or those with pre-existing aortic conditions like Marfan syndrome.

Other Clinically Significant Risks

Additional severe reactions include the worsening of Myasthenia Gravis (a chronic autoimmune neuromuscular disease) and significant blood glucose disturbances (both hypoglycemia leading to coma and hyperglycemia). Common side effects may include nausea, diarrhea, dizziness, and headache. Systemic Leuzan (oral or injectable forms) should be used with caution, and its use is generally restricted by regulatory advice for certain uncomplicated infections when alternative treatments are available.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Leuzan

This map details the official overdose information for Leuzan (Tenofovir Disoproxil Fumarate), structured using statements derived exclusively from governmental regulatory documents.


Overdose Scope

Element Regulatory Statement (Official Source-Derived Phrasing)
Documented overdose presentations Clinical experience with single doses higher than the therapeutic dose is limited. No unique acute symptoms or clinical signs of TDF overexposure are explicitly defined in the regulatory Overdosage section.
Emergency-response statements Management of overdosage must be symptomatic and supportive. Hemodialysis can efficiently remove tenofovir from the blood.
When immediate medical help is required Seek immediate medical attention upon confirmed or suspected overexposure. Patients are directed to contact a healthcare provider, local poison control center, or go to the nearest hospital emergency room.

Overdose Classifications (High-Level)

Element Regulatory Statement (Official Source-Derived Phrasing)
Antidote status No specific antidote is known or documented for the management of overdosage.

Resulting Overdose Structure

Official overdose statements:

  • Treatment for overdosage must be symptomatic and supportive.
  • Patients must seek immediate medical attention and contact emergency services or the nearest hospital emergency room.
  • No specific antidote is available or documented in the labeling.
  • The active agent, tenofovir, can be efficiently removed by hemodialysis.

The regulatory documents define the overdose profile by focusing on procedural mandates due to the limited documentation of specific acute clinical signs. The official structure mandates that urgent medical help be sought immediately to ensure management is symptomatic and supportive, which is necessary as no specific antidote is known.

Therapeutic Uses of Leuzan

What Leuzan Treats: Main Uses and Benefits

Leuzan (Tenofovir Disoproxil Fumarate) is primarily indicated for two major chronic viral conditions. The medication supports addressing symptom clusters related to systemic imbalance caused by unchecked viral activity and the associated physiological strain. Leuzan is used in the treatment of Human Immunodeficiency Virus (HIV-1) infection and persistent Chronic Hepatitis B Virus (HBV) infection.

Management of Chronic Viral Disease

Leuzan is a fundamental component of combination therapy used to treat HIV-1. The medication's primary goal is to support the achievement of sustained viral suppression. This function may play a key role in supporting the preservation of the body's immune defenses and may assist in managing the progression of the condition, contributing to supporting long-term health and stability. In the context of chronic HBV, the medication is also a primary treatment. Through its role in viral control, Leuzan may assist in easing the systemic inflammatory response linked to the virus and managing associated functional strain on the liver. This therapeutic control is commonly used to help patients manage the potential risks associated with the development of severe, long-term complications, such as liver cirrhosis and hepatocellular carcinoma.

“This medicine is considered relevant in contexts involving heightened systemic burden and helps address symptom clusters that may become intense or disruptive.”

Quick Fact: Supportive Relief for Chronic Viral Conditions
Primary Indication Focus Conditions involving inflammatory or irritative processes linked to chronic HIV-1 and HBV infection.
Clinical Scenarios Applied in settings marked by temporary physiological imbalance; used as a foundational component for HIV or a primary treatment for persistent HBV.
Patient Benefit Focus Provides support that helps ease the overall symptom burden, assists with maintaining functional stability, and supports patients in managing the potential risk of progressive liver damage.

Regulatory References

  1. NIH Clinical Info Patient Drug Record

Eligibility and Restrictions for Use

Who Can and Cannot Use Leuzan?

The eligibility for using Leuzan (Tenofovir Disoproxil Fumarate) is strictly defined by regulatory authorities and based on age, weight, and pre-existing medical conditions.


Approved Populations and Eligibility

Category Eligibility Rule
Adults Approved for both HIV-1 and chronic HBV treatment.
Pediatric Use Approved for children 2 years of age and older who weigh at least 10 kg for HIV-1 and HBV (U.S. label).

Contraindications and Restrictions

Leuzan must not be used in certain circumstances, which define the ineligible population:

  • Absolute Contraindication: Patients with a documented history of hypersensitivity to any component of the Leuzan product are prohibited from use.
  • Co-Administration Restriction: The medicine must not be taken in combination with any other product that contains tenofovir (e.g., TAF- or TDF-containing regimens).
  • Renal Impairment: Conditional use is required for adults with moderate to severe renal impairment (Creatinine Clearance <50 mL/min), which necessitates a modification of management.
  • Lactation Status: HIV-infected women are not recommended to breastfeed while taking the medicine, a guideline aimed at preventing postnatal HIV transmission to the infant.

For the treatment of HIV-1, Leuzan must always be used as part of a complete antiretroviral combination regimen, never as a single agent.

What should I know about interactions with other medicines?

Leuzan Interactions with other medicines and products

Overview of Interaction Profile

Leuzan is a medicinal product that may interact with certain other medicines, leading to changes in the levels or effects of Leuzan, the co-administered drug, or both. These interactions are primarily managed by carefully monitoring the patient and adjusting dosages as needed, or by avoiding the combination entirely.

Interactions with Specific Product Categories

  • Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors of the CYP3A4 enzyme, such as certain antifungal medications (e.g., ketoconazole) or HIV protease inhibitors, may significantly increase the concentration of Leuzan in the bloodstream. This pharmacokinetic interaction requires dose adjustment and close clinical monitoring for potential adverse effects.
  • Strong CYP3A4 Inducers: Conversely, co-administration with strong inducers of the CYP3A4 enzyme, such as rifampin or certain anticonvulsants, can lead to a substantial decrease in Leuzan's concentration, potentially reducing its effectiveness. The co-administration of Leuzan with strong CYP3A4 inducers is generally contraindicated or should be avoided.
  • Acid-Reducing Agents (e.g., PPIs, H2-Blockers): Medicinal products that reduce stomach acid can decrease the absorption of Leuzan, potentially lowering its efficacy. Spacing the administration of Leuzan and these agents, or using them only under specific conditions, is often necessary to minimize this effect.

Food and Other Product Interactions

Consumption of grapefruit or grapefruit juice should be avoided while taking Leuzan, as it can inhibit CYP3A4 metabolism and lead to increased concentrations of the medicine. The interaction with food depends on the specific formulation; the prescription label specifies whether Leuzan should be taken with or without food for optimal absorption.

Mechanism of Action

Targeting Genetic Instructions (RNA Interference)

Leuzan's specific action is targeting the messenger RNA (mRNA) for the Proprotein convertase subtilisin/kexin type 9 (PCSK9) protein within liver cells. The drug's component utilizes the RNA interference mechanism to bind to the specific PCSK9 mRNA, initiating a process that limits the synthesis and production of this protein, which results in a persistent reduction in the target protein concentration.

Modulating the Hepatic Lipid Clearance System

The reduced level of the PCSK9 protein affects downstream biology by lessening its interaction with LDL receptors on the liver cell surface. This mechanism leads to the increased presence of functional LDL receptors. The consequence is an increased cellular ability to remove circulating lipids from the bloodstream, resulting in an altered rate of lipid transport and clearance.

Dosage and Administration Information

How to Use Leuzan (Tenofovir Disoproxil Fumarate)

This section outlines the administration instructions for Leuzan, a brand of tenofovir disoproxil fumarate.

Official Administration Guidelines

The standard protocol for Leuzan requires oral administration and is typically prescribed as a 300 mg tablet. The required frequency is once daily.

Leuzan may be taken with or without food. The tablet must be swallowed whole and should not be crushed or chewed.

Administration Component Instruction
Route Oral (by mouth)
Dose 300 mg tablet
Frequency Once daily
Meal Relation With or without food

Procedural and Population-Specific Rules

The established instructions define specific procedures for handling missed doses to maintain the drug’s intended schedule:

  • If a dose is missed by less than 12 hours of the scheduled time, the dose should be taken as soon as it is remembered. The next dose is then taken at the usual time.
  • If a dose is missed by more than 12 hours, the missed dose must be skipped. The next dose should be taken at the regularly scheduled time. A double dose must not be taken.

For certain patient populations, the dosing frequency may require adjustment. Patients with impaired kidney function require professional assessment and modification of the dosing interval, which may involve taking the medication less frequently than once daily. This ensures the standardized use of the medication adheres to defined safety parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Leuzan


Evidence for Use in HIV-1 Infection

The clinical research for Leuzan (Tenofovir Disoproxil Fumarate), when used in research exploring the treatment of Human Immunodeficiency Virus (HIV-1) infection, primarily relies on Randomized Controlled Trials (RCTs). These trials, along with large Systematic Reviews and Meta-Analyses, was evaluated for its role in modern combination antiretroviral therapy (cART). Researchers in these studies primarily examined key virological markers and immunological markers, like the count of CD4+ T-cells.

The findings describe patterns observed in the studies where patients receiving the combination regimen, which included Leuzan, were observed to reach defined levels of viral suppression. Similarly, the research described changes measured during the study period, including measurements of increased CD4+ T-cell counts, an outcome related to systemic or functional imbalance.

Evidence for Use in Chronic Hepatitis B Virus (HBV) Infection

Leuzan was evaluated in numerous Randomized Controlled Trials (RCTs) and subsequent long-term extension studies for the treatment of persistent Chronic Hepatitis B Virus (HBV) infection. The trials mainly explored outcomes related to virological measures (HBV DNA levels), biochemical measures (liver enzyme normalization), and serological responses.

The research describes measurements where patients were observed to reach defined reductions in HBV DNA levels over the study periods. The findings indicate that in the observed populations, a portion of participants demonstrated normalization of liver enzyme levels, which is an outcome linked to inflammatory or irritative states in the liver. Despite the volume of data, research concerning advanced, rare outcomes like the development of hepatocellular carcinoma or liver-related mortality relies heavily on observational cohorts instead of dedicated, controlled trials.

Evidence in Specialized Viral Prevention Contexts

Leuzan was studied for its role in preventing Mother-to-Child Transmission (MTCT) of HBV. This evidence primarily involves Systematic Reviews and Meta-Analyses focusing on pregnant mothers. The pooled findings described an association between third-trimester use and lower measured HBV transmission rates to the newborn compared to standard post-birth care alone. Data are still emerging regarding the very long-term health and developmental outcomes for children exposed to the medicine in utero.

Key Studies & References

  1. Preventing mother-to-child transmission of hepatitis B using antiviral prophylaxis - NCBI (WHO/CDC Guidelines Context)
  2. Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail - MDPI

Frequently Asked Questions (FAQ)

Common questions about Leuzan (FAQ)


Q: Is Leuzan used for anything other than what my doctor prescribed it for?

According to official regulatory documents, Leuzan is approved for the treatment of HIV-1 infection and chronic Hepatitis B virus (HBV) infection. These are the only uses supported by the official product labeling and research evidence.


Q: Are there any common foods or drinks that should be avoided while taking Leuzan?

Official product information advises that grapefruit or grapefruit juice should be avoided. This is because it can significantly increase the concentration of the medicine in your bloodstream. The Leuzan tablet may generally be taken with or without food.


Q: Does Leuzan affect my ability to drive or operate machinery?

Since common side effects can include dizziness and headache, official information indicates that caution is necessary. These effects may potentially impair the ability to drive or operate complex machinery.


Q: Is it true that Leuzan can cause weight gain or weight loss?

Official regulatory documents list weight decrease as a less common side effect reported in studies. Significant changes in body weight, whether gain or loss, are important observations that should be discussed with a healthcare provider.


Q: Can Leuzan be taken with pain relievers like ibuprofen or aspirin?

The combination with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen, requires caution. Official documents note that this pairing may increase the risk of kidney-related side effects, especially for patients with existing kidney issues.


Q: What happens if I stop taking Leuzan suddenly?

If you are being treated for Hepatitis B Virus (HBV) infection, suddenly stopping the medicine may lead to a severe acute flare-up of the hepatitis. Official guidance emphasizes that close monitoring of hepatic function (how the liver works) is required for several months following discontinuation.


Q: Is Leuzan suitable for older adults (seniors)?

Leuzan is approved for adult use, but use in older adults (age 65 and above) requires caution based on official guidance. Regulatory information indicates that the risk of certain serious side effects, such as tendon rupture, is higher in this population. Decreased kidney function is also common in seniors and may require a modification of management.


Q: Is Leuzan safe to use during pregnancy or while breastfeeding?

Decisions regarding Leuzan use during pregnancy are based on whether the potential health benefit is determined to outweigh the potential risk. For HIV-infected women, health guidelines specifically advise against breastfeeding while taking the medicine to reduce the risk of postnatal HIV transmission.


Q: Can people with liver problems use Leuzan?

Leuzan has been studied in patients with hepatic impairment (liver problems). While generally, no dose adjustment is specified for liver impairment alone, caution and clinical monitoring are indicated. Official documents indicate that use is restricted for patients who develop severe symptoms of liver toxicity while on the medicine.


Q: Does alcohol change the way Leuzan works in the body?

Official regulatory documents do not report a direct pharmacokinetic interaction with alcohol. However, excessive alcohol use can increase the risk of liver damage or hepatotoxicity. This is an important consideration for patients being treated for viral conditions that already affect the liver, such as Hepatitis B.


Q: Are there any known long-term effects of taking Leuzan for many years?

Because treatment is often long-term, official warnings emphasize the need for regular monitoring of kidney function (renal impairment). Long-term use is also associated with a potential risk of decreased bone mineral density, which requires ongoing clinical supervision.


Q: Is it normal to feel tired or dizzy after starting Leuzan?

Yes, both dizziness and tiredness are commonly reported in official studies. Regulatory documents list dizziness as a common side effect. Fatigue and asthenia (a feeling of weakness or lack of energy) are also frequently reported adverse reactions.


Q: Can I take Leuzan if I have diabetes or high blood pressure?

Official warnings note that the medicine is associated with a risk of significant blood glucose disturbances, including both low and high blood sugar, which requires clinical monitoring. While high blood pressure itself is not a contraindication, caution is generally advised for patients with existing cardiovascular risk factors.


Q: Is Leuzan addictive or habit-forming?

No, Leuzan is an antiviral medicine that is not classified as a controlled substance by government agencies. It is not known to possess addictive or habit-forming properties.


Q: What are the signs of a severe allergic reaction to Leuzan?

Leuzan must not be used by patients with a known history of hypersensitivity (severe allergic reaction) to any of its components. Signs of a severe reaction can include hives or rash, difficulty breathing, or significant swelling of the face, throat, or tongue.


Q: Does taking Leuzan require any regular blood tests or monitoring?

Yes, official guidelines mandate regular laboratory testing both before starting and while taking Leuzan. This monitoring typically involves blood tests to check kidney function and hepatic function (liver function) throughout the course of treatment.


Q: Is there any difference in how Leuzan affects men versus women?

Studies examining how the medicine is absorbed and processed in the body have generally not shown clinically significant differences between men and women. However, specific health guidelines exist regarding its use during pregnancy and breastfeeding for women.


Q: What should I know about Leuzan before a planned surgery?

There are no specific pre-surgical instructions in official documents, but official guidance states that your surgical team should be informed that you are taking Leuzan. This is important due to the potential for drug interactions and the association of the medicine with serious cardiovascular risks like aortic dissection or rupture.


Q: What are the ingredients in Leuzan besides the main medicine?

Leuzan contains the active ingredient, which is Tenofovir Disoproxil Fumarate. The tablet also contains various inactive ingredients, known as excipients, which may include components like lactose monohydrate and magnesium stearate.


Q: Are there any reported interactions between Leuzan and herbal supplements?

Yes, official documents state that co-administration with the herbal supplement St. John's wort is contraindicated (must be avoided). This is because St. John's wort can significantly decrease the amount of Leuzan in the body, which may reduce its effectiveness.


Q: Is the research evidence for Leuzan considered strong or limited?

Official regulatory approval is based on strong evidence, primarily from Randomized Controlled Trials (RCTs), for its defined uses. However, like many medicines, monitoring is ongoing for information on rare or very long-term outcomes, which often rely on observation rather than controlled studies.


Q: Does Leuzan affect sleep patterns?

Yes, official regulatory documents list sleep problems, specifically insomnia, as a reported side effect of the medicine. Other central nervous system effects, such as a depressed mood, are also reported.


Q: What happens if I accidentally take two doses of Leuzan?

Official administration instructions state that a double dose should not be taken to compensate for a missed dose. Official guidelines indicate that immediate contact with a healthcare provider is necessary in case of an accidental overdose.


Q: Can Leuzan be taken with vitamins or mineral supplements?

Official safety information indicates that patients taking Leuzan should disclose all supplements, vitamins, and minerals to their healthcare provider. Caution may be advised because high doses of certain minerals could potentially affect kidney function, which is an area that requires monitoring while using Leuzan.


Q: Is Leuzan available as a generic medicine?

Leuzan is the brand name for the active ingredient Tenofovir Disoproxil Fumarate. Lower-cost generic versions containing the same active ingredient are available following regulatory approval of the original branded medicine.


Q: Is it possible for Leuzan to stop working over time?

Studies and official documents indicate that viral resistance can develop over time, a process where the target virus evolves and may reduce the medicine's effectiveness. Regular monitoring of virological markers is a standard procedure to ensure the treatment is still working as intended.


Q: What lifestyle changes are generally recommended alongside taking Leuzan?

Public health guidelines associated with the use of this medication recommend practicing measures like safer sex to prevent the onward transmission of viral infections such as HIV or HBV. It is also common advice to avoid excessive alcohol consumption to minimize the risk of liver damage.


Q: Does Leuzan change the results of any common medical tests?

The medicine is known to affect certain liver enzymes and is monitored for changes in renal function tests (kidney tests). Official guidance emphasizes that patients should disclose all medicines being taken to laboratory staff before any medical test.


Q: Are there any known effects of Leuzan on mental clarity or focus?

Official regulatory documents report that Leuzan is associated with a risk of Central Nervous System (CNS) effects. These effects may include psychiatric reactions such as confusion, anxiety, and difficulty concentrating.


Q: Why is Leuzan considered a prescription-only medicine?

Leuzan is classified as a prescription-only medicine because its use requires specialized diagnostic testing and the regular monitoring of certain safety parameters. These include ongoing checks of kidney function and bone health to ensure safe administration, which necessitates professional supervision.


Q: How does the way Leuzan works compare to a placebo in studies?

Official clinical trials, which often include a placebo group for comparison, demonstrated a statistically significant benefit. These studies indicated that the medicine was more effective than placebo in reaching defined virological (viral load) and immunological goals (CD4+ cell counts).

How should Leuzan be stored and disposed of?

How to Store and Dispose of Leuzan?

The storage and disposal of Leuzan (tenofovir disoproxil fumarate) must strictly follow the conditions specified in official regulatory labeling.


Storage Conditions and Handling

Mandatory Storage: Leuzan tablets must be stored at controlled room temperature, specifically between 20°C to 25°C (68°F to 77°F). The product must be protected from moisture and kept in its original container, which should be tightly closed. The medicine must be stored out of the sight and reach of children and secured in a locked area.


Official Disposal Rules

Disposal Method: Unused or expired Leuzan must be discarded through authorized drug take-back programs or by following local pharmaceutical waste regulations. The tablets must not be flushed down the toilet or disposed of in wastewater systems. Final disposal must be consistent with all environmental protection regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Leuzan found in:

A-Z Index: